Your Health, We Care
Exkivity is a targeted therapeutic drug for NSCLC patients with EGFR exon 20 insertion mutation, which has shown significant efficacy in clinical trials.
In October 2023, Takeda Pharmaceuticals announced that it would cooperate with the US FDA to voluntarily withdraw the marketing authorization of Exkivity in the United States. Patients and doctors should consider multiple factors when choosing treatment plans to develop personalized treatment plans that are most suitable for patients.
Scan code
Whatsapp
Exkivity is a targeted drug for the treatment of specific types of lung cancer, specifically developed for the treatment of patients with non-small cell lung cancer (NSCLC) harbori···【more】
Article source：Lucius LaosRelease date：2024-08-06Recommended：260
Exkivity is available in multiple versions, including innovator versions and multiple generic versions. These versions may vary based on factors such as different manufacturers, dr···【more】
Article source：Lucius LaosRelease date：2024-08-06Recommended：227
Exkivity, also known as Mobocertinib, is a novel targeted drug that offers hope to patients with specific types of lung cancer. The launch of Exkivity marks a major step forward in···【more】
Article source：Lucius LaosRelease date：2024-08-06Recommended：272
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
